Systemic inflammatory response index is a predictor of prognosis in gastric cancer patients: Retrospective cohort and meta-analysis

Table 1 The fundamental description of the inclusion studies

Population	Patients	Included years	Detection method	Cut-off value	Survival type (analysis type)	Treatments	Follow- up	HR	LL	UL	NOS score
Localized or regional gastric cancer	782	2007-2009/2010-2011	ROC analysis	0.82	DFS/DSS	With surgery	≥ 5 yr	DFS 2.529	DFS 1.922	DFS 3.326	7
Gastric cancer	594	2011-2016	ROC analysis	0.85	OS	With surgery	≥ 5 yr	OS 2.06	OS 1.6	OS 2.66	8
Respectable gastric cancer	240	2007-2016	X-tile	1.2	DFS/OS	With surgery	≥ 5 yr	OS 1.999/DFS 1.964	OS 1.387/DFS 1.363	OS 2.881/DFS 2.828	8
Locally advanced gastric cancer	89	2010-2018	ROC analysis	0.58	DFS	With surgery and adjuvant chemoradiotherapy	< 5 yr	DFS 3.002	DFS 0.912	DFS 9.882	7
Received neoadjuvant chemotherapy gastric cancer	107	2007-2015	ROC analysis	1.21	DFS/OS	With neoadjuvant chemotherapy and surgery	≥ 5 yr	OS 3.331/DFS 3.437	OS 1.001/DFS 1.059	OS 11.082/DFS 11.149	8
Adenocarcinoma of the esophagogastric junction	302	2008-2010	ROC analysis	0.68	OS	With neoadjuvant chemotherapy and surgery	≥ 5 yr	OS 1.9	OS 1.36	OS 2.64	8

OS: Overall survival; DFS: Disease-free survival; ROC: Receiver operating characteristic; NOS: Newcastle-Ottawa Scale; HR: Hazard ratios; LL: Lower limit; UL: Upper limit.